1. Regulus Therapeutics CEO Jay Hagan to present at biotech summit. 2. Presentation scheduled for April 9th, focusing on microRNA innovations. 3. Live event will be accessible and archived on the company website. 4. Regulus specializes in developing medicines targeting specific microRNAs.
Management's active engagement in public forums like biotech summits can boost stock investor confidence. Historical examples show similar announcements have often led to positive stock movements due to heightened investor interest and potential partnerships.
The presentation indicates ongoing corporate activity, which is crucial for maintaining market interest. Given the innovative focus on microRNA and potential for future drug development, this can significantly attract investor attention.
Immediate positive investor sentiment likely from the upcoming presentation features. Interest in biopharmaceutical advancements tends to spike around such events.
SAN DIEGO, April 2, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, CEO, will participate in a presentation at the 2025 Oppenheimer Innovation on the Island Biotech Summit on Wednesday, April 9th at 11:32 a.m. ET.
The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.